| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Biological Carcinogenesis and Development Program, Program Resources, Inc./DynCorp [R. L. H., M. B.], and the Laboratory of Experimental Immunology [J. W. P.], Biological Response Modifiers Program [D. L. L.], Division of Cancer Treatment, National Cancer Institute-Frederick Cancer Research and Development Center, Frederick, Maryland 21702
We have examined the ability of bryostatin 1 to inhibit the in vitro growth and in vivo development of a panel of four murine tumors of diverse tissue origins. A wide range of antiproliferative responses was observed for the four tumors. At 100 ng/ml the in vitro growth of the Renca renal adenocarcinoma, the B16 melanoma, the M5076 reticulum cell sarcoma, and the L10A B-cell lymphoma were inhibited by 0, 40, 40, and 94% respectively. All three cell lines sensitive to bryostatin in vitro responded to multiple dose, 1 µg/injection/day in vivo i.p., bryostatin therapy. Only the in vitro resistant Renca tumor failed to respond to bryostatin in vivo. The correlation between in vitro and in vivo antitumor efficacy suggests a direct mechanism of antitumor activity for bryostatin. Both local regional therapy (M5076 i.p.) and systemic therapy (B16 lung metastases and L10A s.c. tumors) with bryostatin were successful at prolonging survival time. Multiple i.p. doses of bryostatin at a minimum level of 0.5–1.0 µg/injection were required to observe significant in vivo antitumor effects. The success of in vivo administration of bryostatin in mice bearing 8–10-mm s.c. masses of L10A lymphoma (5–10 x 109) and our further observation that five of a panel of six human B-cell lymphoma cell lines were sensitive to the growth inhibitory effects of bryostatin in vitro suggest that bryostatin may be effective in treating lymphoid malignancies in humans.
1 This project has been funded at least in part with Federal funds from the Department of Health and Human Services under Contract N01-CO-74102 with Program Resources, Inc./DynCorp. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the United States Government. By acceptance of this article, the publisher or recipient acknowledges the right of the United States Government to retain a nonexclusive, royalty-free license in and to any copyright covering the article.
2 To whom requests for reprints should be addressed, at Biological Carcinogenesis and Development Program, Program Resources, Inc./DynCorp, NCI-FCRDC, P. O. Box B. Bldg. 567, Frederick, MD 21702.
Received 5/ 6/91. Accepted 10/22/91.
This article has been cited by other articles:
|
|
 |
|
  J. D. Roberts, M. R. Smith, E. J. Feldman, L. Cragg, M. M. Millenson, G. J. Roboz, C. Honeycutt, R. Thune, K. Padavic-Shaller, W. H. Carter, et al. Phase I Study of Bryostatin 1 and Fludarabine in Patients with Chronic Lymphocytic Leukemia and Indolent (Non-Hodgkin's) Lymphoma. Clin. Cancer Res., October 1, 2006; 12(19): 5809 - 5816. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Li, W. Wojciechowski, C. Dell'Agnola, N. E. Lopez, and I. Espinoza-Delgado IFN-{gamma} and T-bet Expression in Human Dendritic Cells from Normal Donors and Cancer Patients Is Controlled through Mechanisms Involving ERK-1/2-Dependent and IL-12-Independent Pathways J. Immunol., September 15, 2006; 177(6): 3554 - 3563. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Wojciechowski, H. Li, S. Marshall, C. Dell'Agnola, and I. Espinoza-Delgado Enhanced Expression of CD20 in Human Tumor B Cells Is Controlled through ERK-Dependent Mechanisms J. Immunol., June 15, 2005; 174(12): 7859 - 7868. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Dowlati, H. M. Lazarus, P. Hartman, J. W. Jacobberger, C. Whitacre, S. L. Gerson, P. Ksenich, B. W. Cooper, P. S. Frisa, M. Gottlieb, et al. Phase I and Correlative Study of Combination Bryostatin 1 and Vincristine in Relapsed B-Cell Malignancies Clin. Cancer Res., December 1, 2003; 9(16): 5929 - 5935. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. De Lorenzo, K. Yamaguchi, K. Subbaramaiah, and A. J. Dannenberg Bryostatin-1 Stimulates the Transcription of Cyclooxygenase-2: Evidence for an Activator Protein-1-Dependent Mechanism Clin. Cancer Res., October 15, 2003; 9(13): 5036 - 5043. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. B. Haas, M. Smith, N. Lewis, L. Littman, G. Yeslow, I. D. Joshi, A. Murgo, J. Bradley, R. Gordon, H. Wang, et al. Weekly Bryostatin-1 in Metastatic Renal Cell Carcinoma: A Phase II Study Clin. Cancer Res., January 1, 2003; 9(1): 109 - 114. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. H. Cragg, M. Andreeff, E. Feldman, J. Roberts, A. Murgo, M. Winning, M. B. Tombes, G. Roboz, L. Kramer, and S. Grant Phase I Trial and Correlative Laboratory Studies of Bryostatin 1 (NSC 339555) and High-Dose 1-B-D-Arabinofuranosylcytosine in Patients with Refractory Acute Leukemia Clin. Cancer Res., July 1, 2002; 8(7): 2123 - 2133. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. W. Otieno, C. Banura, E. Katongole-Mbidde, J. L. Johnson, M. Ghannoum, A. Dowlati, R. Renne, E. Arts, C. Whalen, M. M. Lederman, et al. Therapeutic Challenges of AIDS-Related Non-Hodgkin's Lymphoma in the United States and East Africa J Natl Cancer Inst, May 15, 2002; 94(10): 718 - 732. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. E. Curiel, C. S. Garcia, L. Farooq, M. F. Aguero, and I. Espinoza-Delgado Bryostatin-1 and IL-2 Synergize to Induce IFN-{gamma} Expression in Human Peripheral Blood T Cells: Implications for Cancer Immunotherapy J. Immunol., November 1, 2001; 167(9): 4828 - 4837. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Rabah, S. Grant, C. Ma, and D. H. Conrad Bryostatin-1 Specifically Inhibits In Vitro IgE Synthesis J. Immunol., November 1, 2001; 167(9): 4910 - 4918. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Vrana and S. Grant Synergistic induction of apoptosis in human leukemia cells (U937) exposed to bryostatin 1 and the proteasome inhibitor lactacystin involves dysregulation of the PKC/MAPK cascade Blood, April 1, 2001; 97(7): 2105 - 2114. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Mohammad, N. R. Wall, J. A. Dutcher, and A. M. Al-Katib The Addition of Bryostatin 1 to Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) Chemotherapy Improves Response in a CHOP-resistant Human Diffuse Large Cell Lymphoma Xenograft Model Clin. Cancer Res., December 1, 2000; 6(12): 4950 - 4956. [Abstract] [Full Text]
|
|
|
|
|
|
J. A. Koutcher, M. Motwani, K. L. Zakian, X.-K. Li, C. Matei, J. P. Dyke, D. Ballon, H. H. Yoo, and G. K. Schwartz The in Vivo Effect of Bryostatin-1 on Paclitaxel-induced Tumor Growth, Mitotic Entry, and Blood Flow Clin. Cancer Res., April 1, 2000; 6(4): 1498 - 1507. [Abstract] [Full Text]
|
|
|
|
|
|
S. Weitman, A.-M. Langevin, R. L. Berkow, P. J. Thomas, C. A. Hurwitz, A. S. Kraft, R. L. Dubowy, D. L. Smith, and M. Bernstein A Phase I Trial of Bryostatin-1 in Children with Refractory Solid Tumors: A Pediatric Oncology Group Study Clin. Cancer Res., September 1, 1999; 5(9): 2344 - 2348. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Bosco, S. Rottschafer, L. S. Taylor, J. R. Ortaldo, D. L. Longo, and I. Espinoza-Delgado The Antineoplastic Agent Bryostatin-1 Induces Proinflammatory Cytokine Production in Human Monocytes: Synergy With Interleukin-2 and Modulation of Interleukin-2Rgamma Chain Expression Blood, May 1, 1997; 89(9): 3402 - 3411. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
